2016 News Releases
CSL CEO Says Holistic Approach to Business is Essential to Corporate Sustainability, the Company's Value Chain and Patients
CSL released its 2015-2016 Corporate Responsibility Report, which details company performance in key social, environmental and economic priority areas.
Health Canada Approves CSL Behring’s AFSTYLA™ for the Treatment of Hemophilia A
Health Canada has approved AFSTYLA, CSL Behring’s novel long-lasting recombinant factor VIII single-chain therapy for adults and children with hemophilia A.
CSL Behring Presents New Phase III Analysis of IDELVION® for Hemophilia B at the 2016 American Society of Hematology Annual Meeting
Global biotherapeutics leader CSL Behring today announced new results from its Phase III clinical development program evaluating IDELVION® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein], the company’s novel, long-acting recombinant albumin fusion protein for the treatment of hemophilia B.
The Lancet Respiratory Medicine Publishes RAPID Extension Study Data Confirming Disease-modifying Effect of Respreeza® [Alpha1-Proteinase Inhibitor (Human)] in Patients with Alpha-1 Antitrypsin Deficiency (AATD)
CSL Behring’s RAPID Extension Study data confirms disease-modifying effect of Respreeza® in patients with AATD.
CSL Behring Presents Positive Results from the CSL112 AEGIS-I Phase 2b Trial
AEGIS-1 Phase 2b study meets co-primary endpoints of hepatic and renal safety and demonstrates proof of mechanism - results were presented at AHA 2016.
AFSTYLA®, for Haemophilia A, Receives Positive Opinion from European Medicines Agency CHMP
Global biotherapeutics leader CSL Behring announced today that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorisation for AFSTYLA® [Recombinant Human Coagulation Factor VIII, Single Chain] for patients with haemophilia A.
CSL Behring Receives 2016 Marcum Innovator Breakthrough Award for Pioneering New Advancements in the Biotech/Healthcare Field
One of the world’s top specialty biotherapeutics companies, CSL Behring continues to introduce innovations to address unmet medical needs or enhance current treatments
Many Rare Disease Patients Would Not Have Treatments Available to Them without an Adequate Supply of Human Plasma
Many Rare Disease Patients Would Not Have Treatments Available to Them without an Adequate Supply of Human Plasma, and patients call plasma donors "heroes" for their lifesaving contributions.
Therapeutic Goods Administration Approves IDELVION® - CSL Behring’s Novel Recombinant Haemophilia B Treatment with up to 14-day Dosing Intervals
CSL Behring announced that the Australian Therapeutic Goods Administration (TGA) has approved IDELVION®[albutrepenonacog alfa] in patients with haemophilia B (congenital factor IX deficiency).
Japan’s Ministry of Health, Labour and Welfare (MHLW) Approves CSL Behring’s IDELVION® -- The First and Only Hemophilia B Therapy with Up to 14-day Dosing Intervals
Global biotherapeutics leader CSL Behring announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved IDELVION® [Albutrepenonacog Alfa], its innovative, long-acting albumin fusion protein linking recombinant coagulation factor IX with recombinant albumin for the prevention of bleeding tendency in patients with factor IX deficiency.
CSL Behring Reinforces Global Leadership at the 17th Biennial Meeting of the European Society for Immunodeficiencies (ESID)
CSL Behring is proud to be a platinum sponsor of the 17th Biennial Meeting of the European Society for Immunodeficiencies (ESID) this week in Barcelona
General Counsel Greg Boss of Global Biotherapeutics Leader CSL Limited Receives Career Honor from Directors Roundtable
General Counsel Greg Boss of global biotherapeutics leader CSL Limited today accepted the World Recognition of Distinguished General Counsel from the Directors Roundtable in recognition of his professional accomplishments and passion for ethical leadership
CSL Behring Provides Leadership at Global Congress
CSL Behring is hosting an Expert Forum "Modifying Alpha-1 Antitrypsin Deficiency Related Emphysema" today during the 26th International Congress of the European Respiratory Society (ERS) in London.
FDA Accepts CSL Behring’s Biologics License Application for First Subcutaneous Prophylactic Therapy to Prevent Hereditary Angioedema Attacks
The U.S. Food and Drug Administration (FDA) has accepted CSL Behring’s application for its low volume subcutaneous (SC) C1-Esterase Inhibitor (C1-INH) Human replacement therapy for treating HAE. Upon FDA approval, CSL830 will be the first and only low volume, subcutaneous, prophylactic treatment option for HAE patients.
CSL Behring Presents Pivotal Efficacy Data for AFSTYLA® In Adolescents and Children with Hemophilia A at the World Federation of Hemophilia 2016 World Congress
CSL Behring today presented data from a Phase III pivotal study of AFSTYLA® [Antihemophilic Factor (Recombinant), Single Chain] in hemophilia A patients less than 12 years of age at the XXXII International Congress of the World Federation of Hemophilia (WFH) in Orlando, Fla.
CSL Behring Presents Phase III Data for IDELVION® for Hemophilia B at the World Federation of Hemophilia 2016 World Congress
CSL Behring today announced new data from its Phase III PROLONG-9FP clinical development program evaluating IDELVION® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein], the company’s novel, long-acting recombinant albumin fusion protein for treating hemophilia B.
CSL Behring Awards Emerging Coagulation Specialists Across the Globe to Support Advancements in the Care of Patients with Bleeding Disorders
CSL Behring today announced that the company has named five recipients of the 2016 CSL Behring Professor Heimburger Award for coagulation research at the XXXII International Congress of the World Federation of Hemophilia (WFH) in Orlando, Fla.
CSL Behring to Present New Data for IDELVION® and AFSTYLA® at the World Federation of Hemophilia 2016 World Congress
CSL Behring announced today that it will present new data from its recombinant coagulation factor development programs at the XXXII International Congress of the World Federation of Hemophilia (WFH) in Orlando, Fla., July 24 – 28, 2016.
U.S. FDA Approves CSL Behring’s Berinert® as the First and Only Pediatric Treatment for Hereditary Angioedema (HAE)
CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has approved the use of Berinert [C1 Esterase Inhibitor (Human)], its therapy for treating Hereditary Angioedema (HAE) attacks, for use in pediatric patients.
CSL Behring Announces Immunoglobulin Research Grant Winners
CSL Behring announced today at the Peripheral Nerve Society’s Inflammatory Neuropathy Consortium (INC) meeting at the University of Glasgow, Scotland, the winners of its annual Interlaken Leadership Awards.